cutaneous T-cell lymphoma
Oncology · 2011–2025
9decisions
4medicines
4carried consumer input
25individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mogamulizumab Treatment of relapsed or refractory cutaneous T-cell lymphoma (mycosis fungoides or Sezary syndrome) previously treated with at least one prior systemic… | Sep 2025 | Noted | 15 individuals Leukaemia Foundation · Rare Cancers Australia |
| methoxsalen Treatment of patients with erythrodermic stage III-IVa T4M0 cutaneous T-cell lymphoma (CTCL) who are refractory to one or more systemic treatments, delivered… | May 2020 | Recommended with restriction | no section in document |
| mogamulizumab Relapsed or refractory cutaneous T-cell lymphoma (mycosis fungoides or Sézary syndrome) after at least one prior systemic treatment. | Nov 2020 | Not recommended | input received Leukaemia Foundation |
| brentuximab vedotin Treatment of adult patients with relapsed or refractory CD30 positive cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. | Jul 2018 | Not recommended | 8 individuals |
| brentuximab vedotin Treatment of refractory or relapsed CD30 positive cutaneous T-cell lymphomas (CTCL) in patients who have received prior systemic treatment. | Nov 2018 | Recommended with restriction | none received |
| methoxsalen Treatment of cutaneous T-cell lymphoma (CTCL), specifically erythrodermic stage T4 M0 (stage III-IVa) disease that is refractory to one or more systemic… | Jul 2017 | Deferred | none received |
| vorinostat Cutaneous T-cell lymphoma (CTCL) in patients with relapsed or chemotherapy-refractory disease who are ineligible for stem cell transplantation and have… | Mar 2017 | Recommended with restriction | none received |
| vorinostat Treatment of relapsed or chemotherapy-refractory cutaneous T-cell lymphoma (CTCL) in patients who have received and failed prior systemic therapy, are not… | Nov 2016 | Deferred | 2 individuals Rare Cancers Australia |
| vorinostat Advanced stage (stage IIB-IV) cutaneous T-cell lymphoma, where treatment has failed with four systemic therapies. | Mar 2011 | Not recommended | unclear |
Who spoke
Leukaemia Foundation · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 8 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.